CAMP vs CBIO

CAMP4 THERAPEUTICS CORPORATION vs Crescent Biopharma, Inc. — Valuation Comparison 2026

CAMP

Pharmaceutical Preparations
CAMP4 THERAPEUTICS CORPORATION
Quality
6.1
out of 10
Value Trap
18
SAFE
Price
$4.39
Last close
Models
9/13
Active
VS

CBIO

Pharmaceutical Preparations
Crescent Biopharma, Inc.
Quality
5.3
out of 10
Value Trap
12
SAFE
Price
$20.65
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CAMP Fair ValueCAMP Upside CBIO Fair ValueCBIO Upside
Bayesian DCF Intrinsic $0.51 -88.3% $8.25 -60.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.83 -58.4% $4.01 -80.6%
Dynamic NAV Asset-Based $1.44 -64.6% $8.97 -56.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CAMP vs CBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CAMP vs CBIO — Which Stock Is More Undervalued?

CAMP scores higher with a 6.1/10 quality rating vs CBIO's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CAMP4 THERAPEUTICS CORPORATION (CAMP) and Crescent Biopharma, Inc. (CBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CAMP currently trades at $4.39 with a QOC of 6.1/10, while CBIO trades at $20.65 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).